SubscribeLogin
curetoday.com image

News from curetoday.com

We’ve assigned a media bias rating of to curetoday.com. You can read more about our methodology here.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)
Cancer · United States

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)

67% Center coverage: 3 sources
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death l…See the Story
Mesoblast's RYONCIL Makes History: First MSC Therapy FDA-Approved with 70% Response Rate in Critical Child Disease
History · United States

Mesoblast's RYONCIL Makes History: First MSC Therapy FDA-Approved with 70% Response Rate in Critical Child Disease

Breakthrough therapy RYONCIL receives historic FDA approval for treating steroid-resistant GvHD in children, showing remarkable 70% response rate in clinical trials.See the Story
FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC
FDA · United States

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal